Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal

Boehringer Ingelheim is heading out into the surf with Australia's Kinoxis Therapeutics in a $181 million biobucks deal to develop therapies for neuropsychiatric disorders.

The German pharma will work with the small Melbourne-based biotech to develop small molecule oxytocin-targeting precision psychiatry treatments, according to a Friday press release. The goal of these treatments is to target the brain oxytocin system to treat disrupted social behavior.